Tarsus targets mites driving inflammatory eye disease with $60M series B

Tarsus thinks its topical therapy against the parasite behind nearly half of blepharitis cases could become the first drug approved

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE